Update on Immune Checkpoint Inhibitor-Associated Uveitis

AbstractPurpose of ReviewIn this article, we review the current updates on immune checkpoint inhibitors (ICPIs) and the management of ICPI-associated uveitis.Recent FindingsICPI-associated uveitis usually presents within 6  months of ICPI initiation. The spectrum of vision loss ranges from mild to severe, and may be as poor as light perception. In recent years, various societies have published guidelines with updated management recommendations for ICPI-associated uveitis. Steroids and cessation of ICPI administration remain the mainstays of treatment. The visual prognosis is generally good with appropriate treatment. Recalcitrant inflammation or secondary effects from steroid therapy may contribute to vision loss.SummaryICPI-associated uveitis may be vision-threatening in some patients, but often exhibits a significant response to steroid therapy. Treatment of ICPI-associated uveitis requires a multidisciplinary approach. Patients who are suspected to have ICPI-associated uveitis should be referred to a uveitis specialist.
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research